– USA, MA – PureTech Health plc (Nasdaq: PRTC / LON: PRTC), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the appointment of Dr. Raju Kucherlapati (Ph.D.) as Chair of the Board of Directors, effective immediately.
About Dr. Raju Kucherlapati
Dr. Kucherlapati has served as a member of PureTech’s Board of Directors since 2014. He is currently Chair of the Board’s Nomination Committee and sits on the Audit and Remuneration Committees. Dr. Kucherlapati will continue his current Board committee responsibilities until a replacement is identified at an appropriate time. The Company is actively engaged in a search to expand its independent Board membership and has had several promising conversations. An update will be provided in due course.
Dr. Raju Kucherlapati said: “It has been an honor to serve as interim Chair of PureTech at such an exciting time for the business. The Company successfully delivered against its milestones in 2023 and remains dedicated to identifying and developing medicines with the potential to transform lives. I look forward to continuing in my role as Chair and leveraging my expertise, alongside the rest of the Board, to guide the Company going forward.”
Dr. Raju Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and serves on the Board of Directors of KEW Inc. He was a founder and formerly a board member of Abgenix, Cell Genesys, and Millennium Pharmaceuticals.
He was the first scientific director of the Harvard-Partners Center for Genetics and Genomics. He is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine.
Dr. Raju Kucherlapati received his PhD from the University of Illinois. He trained at Yale and has held faculty positions at Princeton University, the University of Illinois College of Medicine, and the Albert Einstein College of Medicine. He was a member of the Presidential Commission for the Study of Bioethical Issues during the Obama administration.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more: https://puretechhealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.